TY - JOUR
T1 - Novel treatment strategies utilizing immune reactions against chronic myelogenous leukemia stem cells
AU - Matsushita, Maiko
N1 - Publisher Copyright:
© 2021 by the author. Licensee MDPI, Basel, Switzerland.
PY - 2021/11/1
Y1 - 2021/11/1
N2 - Introduction of tyrosine kinase inhibitors (TKIs) has improved the prognosis of patients with chronic myelogenous leukemia (CML), and treatment-free remission (TFR) is now a treatment goal. However, about half of the patients experience molecular relapse after cessation of TKIs, suggesting that leukemic stem cells (LSCs) are resistant to TKIs. Eradication of the remaining LSCs using immunotherapies including interferon-alpha, vaccinations, CAR-T cells, and other drugs would be a key strategy to achieve TFR.
AB - Introduction of tyrosine kinase inhibitors (TKIs) has improved the prognosis of patients with chronic myelogenous leukemia (CML), and treatment-free remission (TFR) is now a treatment goal. However, about half of the patients experience molecular relapse after cessation of TKIs, suggesting that leukemic stem cells (LSCs) are resistant to TKIs. Eradication of the remaining LSCs using immunotherapies including interferon-alpha, vaccinations, CAR-T cells, and other drugs would be a key strategy to achieve TFR.
KW - Chronic myelogenous leukemia
KW - Immunotherapy
KW - Leukemic stem cells
UR - http://www.scopus.com/inward/record.url?scp=85117960623&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85117960623&partnerID=8YFLogxK
U2 - 10.3390/cancers13215435
DO - 10.3390/cancers13215435
M3 - Review article
AN - SCOPUS:85117960623
VL - 13
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 21
M1 - 5435
ER -
